Poor Prognosis of Children With Pre-B Acute Lymphoblastic Leukemia Is Associated With the t(1;19)(q23;p13): A Pediatric Oncology Group Study


The prognostic significance of chromosomal translocations, particularly t(1;19) (q23;p13), was evaluated in children with pre-B and early pre-B acute lymphoblastic leukemia (ALL). Patients were treated on a risk-based protocol of the Pediatric Oncology Group (POG) between February 1986 and May 1989. An abnormal clone was detected in 46% (130 of 285) of pre-B cases and 56% (380 of 679) of early pre-B cases. Translocation of any type was associated with a worse treatment outcome than other karyotypic abnormalities: 15 of 66 versus 3 of 64 failed therapy in the pre-B group (P < .001), and 37 of 141 versus 23 of 239 failed in the early pre-B group (P < .001). The t(1;19) (q23;p13) occurred significantly more often in cases of pre-B ALL with a clonal abnormality than in early pre-B ALL cases (29 of 130 v 5 of 380, p < .001). Among the 285 pre-B cases in which bone marrow was studied cytogenetically, those with t(1;19) had a significantly worse treatment outcome than all others (11 of 29 v 27 of 256 have failed therapy, P < .001). This difference is significant (P < .001) after adjustment for leukocyte count, age, and other relevant features. Cases with the t(1;19) also had a worse prognosis than pre-B patients with other translocations (4 of 37 have failed, P < .01) or with any other karyotypic abnormality (7 of 101 have failed, P < .001). We conclude that chromosomal translocations confer a worse prognosis for non-T, non-B-cell childhood ALL, and that the t(1;19) is largely responsible for the poor prognosis of the pre-B subgroup.

© 1990 by The American Society of Hematology.

MATERIALS AND METHODS

Presenting features and clinical outcome were assessed in 285 children with pre-B ALL and 679 with early pre-B ALL who were entered on the POG 8602 (ALinC 14) between February 1986 and May 1989, and had cytogenetic studies attempted in a central reference laboratory at the University of Alabama at Birmingham (UB). Ten additional patients with early pre-B and nine with pre-B ALL are excluded from these analyses because of the unavailability of bone marrow for cytogenetic analysis. Children with B-cell or T-cell ALL and infants (less than 1 year of age) are excluded from this protocol and treated on phenotype- or age-directed therapy. Patients were stratified by risk group (see Table 1) and immunophenotype (early pre-B or pre-B). Informed consent was obtained from the patients, their parents, or both, as deemed appropriate. Those with early pre-B ALL were eligible for randomization after remission induction to receive standard continuation therapy with intermediate-dose methotrexate (IDM) (regimen A, see Fig 1), regimen A

From St Jude Children's Research Hospital and the University of Tennessee, Memphis College of Medicine; University of Alabama at Birmingham; Pediatric Oncology Group Statistical Office and the University of Florida, Gainesville; McGill University School of Medicine, Montreal, Quebec, Canada; Washington University Medical Center, St Louis, MO; Baylor University School of Medicine, Houston, TX; Emory University School of Medicine, Atlanta, GA; and University of Mississippi Medical Center, Jackson, MS.

Submitted November 10, 1989; accepted March 2, 1990.

Supported in part by grants from the National Cancer Institute, National Institutes of Health (CA 21765 [CORE]; CA 31566, CA 25408, CA 30969, CA 20549, CA 29139, CA 03161, CA 15989, CA 05587, and CA 33587), and by the American Lebanese Syrian Associated Charities (ALSAC).

Presented in part at the annual meeting of the American Society of Hematology, Atlanta, GA, 1989.

Address reprint requests to the Pediatric Oncology Group Operations Office, 4945 West Pine Blvd, Suite A 2nd Floor, St Louis, MO 63108.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1990 by The American Society of Hematology. 0006-4971/90/7601-0006$3.00/0

Blood, Vol 76, No 1 (July 1), 1990: pp 117-122
plus intensive L-asparaginase (regimen B); regimen A plus high-dose cytarabine (regimen C); or with IDM and cytarabine spread out over the first 18 months of therapy (regimen D). All patients received “backbone” therapy with oral 6-mercaptopurine and intramuscular methotrexate. Central nervous system (CNS) preventive therapy consisted of triple intrathecal therapy (hydrocortisone, methotrexate, cytarabine).

Randomization of patients with pre-B ALL was restricted to regimen B or C because of the relatively small numbers of cases. Of the 294 children with pre-B ALL, 89 are receiving regimen B and then randomized to regimen B or C. The reason for the late opening of regimen B was that the intensive L-asparaginase therapy regimen required additional piloting.

Of 689 children with early pre-B ALL, 111 were assigned to regimen A, 130 to regimen B, 229 to regimen C, and 188 to regimen D (31 are awaiting randomization). The unequal distribution of early pre-B patients is due to randomization of high-risk patients only to regimens B, C, and D, and the late opening of regimen B. The 10 patients with early pre-B ALL and the nine with pre-B ALL who did not have a sample of bone marrow sent for cytogenetic analysis are included in this summary of treatment assignments, but not in any of the analyses in this report. They remain on study but are not included in this report since we wish to focus on those children who had centrally performed cytogenetic studies.

**Cytochemistry and immunologic cell markers.** Leukemic cells were examined morphologically and classified according to French-American-British (FAB) criteria. In addition, cells were examined for cytochemical reactivity to Sudan-black B, myeloperoxidase, and nonspecific esterase by standard techniques. Bone marrow cells were sent to St Jude Children’s Research Hospital (SJCRH, Memphis, TN) Cell Marker Reference Laboratory for clg and sig testing as previously described. Only cytoplasmic μ (not other heavy chain classes) was assessed. HLA-DR and common ALL (CALLA) antigens were identified at Duke University’s Immunology Reference Laboratory (Durham, NC) by a standard immunofluorescence method using flow cytometric analysis and monoclonal antibodies (MoAbs). T-cell phenotyping was performed at the Stanford University Reference Laboratory (Palo Alto, CA) by standard immunofluorescence methods using MoAbs (CD3, CD5, CD7) with flow cytometry.

### Table 1. Criteria for Risk Classification

<table>
<thead>
<tr>
<th>Feature</th>
<th>Age (y)</th>
<th>&lt;1</th>
<th>1-2</th>
<th>3-6</th>
<th>6-10</th>
<th>&gt;10</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC level (× 10^9/L)</td>
<td></td>
<td>B</td>
<td>A</td>
<td>A</td>
<td>A</td>
<td>B</td>
</tr>
<tr>
<td>Liver or spleen below umbilicus; extramedullary leukemia</td>
<td></td>
<td>B</td>
<td>B</td>
<td>B</td>
<td>B</td>
<td>B</td>
</tr>
</tbody>
</table>

Abbreviations: A, good-risk group; B, poor-risk group.

---

![Fig 1. Schema of therapy on AlinC 14 (POG 8602) treatment protocol for patients with newly diagnosed non-T, non-B-cell ALL, excluding infants (<12 months of age). Remission induction: Regimens A to D: prednisone (PRED), 40 mg/m² day orally (maximum dose, 60 mg) × 28 days; vincristine (VCR), 1.5 mg/m² intravenously once weekly × 4; L-Asparaginase (ASp), 6,000 U/m² intramuscularly (IM) three times weekly × 6; 6-mercaptopurine (6-MP), 75 mg/m² orally × 14 days (days 29 to 43). Triple intrathecal therapy (TIT) with hydrocortisone 15 mg, methotrexate (MTX) 15 mg, and cytosine arabinoside (ARA-C) 30 mg for ages greater than 9 years (scaled down for younger children); administered on days 1 and 2 of induction treatment, days 29 and 36 of CNS intensification, and therefore on weeks 9, 12, 15, 18, and every 9 weeks through week 105§. Intensification: Regimen A: intermediate-dose MTX (IDM), 1 g/m² over 24 hours with leucovorin rescue weeks 7, 10, 13, 16, 19, and 22. Regimen B: same as regimen A plus ASP, 25,000 U/m² weekly from week 7 to 30 IM. Regimen C: exactly as regimen A plus ARA-C 1 g/m² over 24 hours, overlapping with IDM by 12 hours. Regimen D: IDM plus ARA-C at same doses as in regimen C but administered every 12 weeks for six courses (weeks 7, 19, 31, 43, 55, and 67) with daily oral 6-MP§ and weekly IM MTX beginning 3 weeks after and continuing until 2 weeks before each IDM/ARA-C course. Continuation therapy: Regimens A, B, and C: MTX 20 mg/m² IM weekly and daily 6-MP orally weeks 25 to 156. Regimen D: 6-MP and MTX weeks 70 to 156. Pulsat: PRED and VCR at same doses as administered in induction; VCR weekly × 2 and PRED daily orally × 7 at weeks 8, 17, 25, 41, 57, 73, 89, and 105.](www.bloodjournal.org)
**Immunologic classification.** All newly diagnosed cases of ALL were classified as pre-B, B, T, or early pre-B ALL according to the following criteria: pre-B, ≥10% of marrow lymphoblasts sIg'; B, ≥10% of marrow lymphoblasts sIg'; and T, CD5, or CD7 without HLA-DR expressed on ≥20% of the leukemic blasts. The early pre-B group included all patients with ALL who had complete immunophenotyping and were not classified by the above criteria, regardless of the expression of CALLA or HLA-DR.

**Cytogenetics.** Cytogenetic studies were performed at a central reference laboratory (UAB). Samples (usually bone marrow) were placed in sterile tubes containing RPMI 1640 supplemented with 15% fetal calf serum and shipped overnight to the cytogenetic laboratory. On arrival, cells were placed in fresh medium and subjected to short-term (24-hour) culture at 37°C. The cells were then exposed to colcemid (0.05 μg/mL) for 2.5 hours at 4°C. Routine methods were used for culture harvest, slide preparation, and GTG-banding. In every case, an attempt was made to completely analyze a minimum of 20 metaphase cells. A clone was defined as: (1) two or more metaphases with an identical structural abnormality; (2) two or more metaphases with an identical extra chromosome; or (3) three or more metaphases with an identical missing chromosome. Cytogenetic results were subgrouped for the present analyses as follows: normal (satisfactory banding, with no clonal abnormality detected); t(1;19) present; other translocation present with t(1;19) excluded; other clonal abnormality present (all translocations excluded); and unassignable (no karyotype determined).

**Statistical analysis.** The design of the ALInC 14 study was based in part on the results of our previous ALInC 13 study, in which children with pre-B ALL had a worse prognosis than those with early pre-B ALL. Therefore, we planned to compare the event-free survival (EFS) for children with early pre-B or pre-B ALL by risk group and immunophenotype (early pre-B or pre-B) according to treatment designated groups (A to D). Infants less than 1 year of age did not enter this study.

Because data regarding the presence or absence of a chromosomal translocation, presence of a clonal abnormality, and presence of the t(1;19) were known for over one half of these patients, we performed a retrospective analysis of the potential effect of these variables on treatment outcome within each phenotype.

**RESULTS**

**Clinical and biologic characteristics.** The distribution of karyotypic findings is shown in Table 2. Successful karyotypes were obtained for 214 of 285 (75%) children with pre-B and 526 of 679 (77%) with early pre-B ALL. Clonal abnormalities were noted in 130 patients (46%) with pre-B and 380 (56%) with early pre-B ALL. Among the 285 children with pre-B ALL who had a sample sent to the reference laboratory for cytogenetic evaluation, 29 had a t(1;19), 37 had a translocation other than t(1;19), 64 had some other clonal abnormality, 84 had a normal karyotype, and in 71 karyotyping was unsuccessful. Among the patients with early pre-B ALL, 5 had a t(1;19), 136 had a translocation other than t(1;19), 239 had some other clonal abnormality, and the remaining patients had a normal karyotype (n = 146) or no karyotype was obtained (n = 153). Among cases with a demonstrated clonal abnormality, the t(1;19) (q23;p13) occurred significantly more often in pre-B than in early pre-B ALL (22% v 1%, P < .001).

<table>
<thead>
<tr>
<th>Table 2. Distribution of Karyotypic Findings</th>
<th>Pre-B (n = 285)</th>
<th>Early Pre-B (n = 679)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Successfully karyotyped</td>
<td>214</td>
<td>526</td>
</tr>
<tr>
<td>Normal karyotype</td>
<td>84</td>
<td>146</td>
</tr>
<tr>
<td>Clonal abnormality</td>
<td>130</td>
<td>380</td>
</tr>
<tr>
<td>Translocation other than t(1;19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t(1;19)</td>
<td>37 (29%)</td>
<td>136 (36%)</td>
</tr>
<tr>
<td>t(1;19)</td>
<td>29 (22%)</td>
<td>5 (1%)</td>
</tr>
<tr>
<td>Other abnormality</td>
<td>64 (49%)</td>
<td>239 (63%)</td>
</tr>
</tbody>
</table>

All patients with pre-B or early pre-B ALL who had bone marrow samples sent to UAB cytogenetic reference laboratory. Nine additional children with pre-B ALL and 10 with early pre-B ALL were entered on study but are excluded from these analyses because no cytogenetic samples were sent to the cytogenetic reference laboratory for analyses.

In general, the presence of a translocation was associated with a worse treatment outcome than were other karyotypic abnormalities: 15 of 66 versus 3 of 64 failed therapy within the pre-B group (P = .001), and 37 of 141 versus 23 of 239 within early pre-B ALL (P < .001; see Fig 2). However, among cases of pre-B ALL, those with the t(1;19) had a worse EFS than those with other translocations (11 of 29 v 4 of 37 have failed therapy, P = .01; see Fig 3). In fact, if children with pre-B ALL and t(1;19) are removed from the pre-B ALL cohort, the remaining children with translocations fare no worse than those with a normal karyotype or those with any clonal abnormality except a t(1;19). None of the five cases with the t(1;19) and an early pre-B cell phenotype have failed as of yet.

The 29 pre-B cases with an identified t(1;19) had a significantly worse treatment outcome than all other pre-B cases (11 of 29 v 27 of 256 have failed therapy, respectively, P < .001, see Fig 3). Also, patients with the t(1;19) had a worse prognosis than pre-B cases with any other detectable cytogenetic abnormality (11 of 29 v 7 of 101 have failed, P < .001; see Fig 3). Their worse treatment outcome remains significant even after stratifying on an individual basis by risk group, leukocyte count, age, race, and DNA index ≥1.16; all analyses achieved significance at the P < .001 level.
except DNA index (P = .015) by logrank analysis. Finally, after adjustment for treatment was made for patients with pre-B ALL, EFS remained significantly worse for those with a t(1;19) compared to all other pre-B cases with a demonstrated clonal abnormality and to all other pre-B patients, regardless of cytogenetic findings, P < .001 for both comparisons. These data show the independent prognostic importance of t(1;19).

If cases with the t(1;19) are excluded from patients in both immunophenotypic groups with clonal abnormalities detected, the prognoses of children with pre-B ALL (n = 101) are significantly better than those of children with early pre-B ALL (n = 375, P = .02).

Within the group of children with pre-B ALL, those with a t(1;19) were significantly more likely to be black (12 of 29 v 28 of 256, P < .001) and to have higher leukocyte counts (median, 25 × 10⁹/L v 14 × 10⁹/L, P = .026 by two-sided Wilcoxon test).

DISCUSSION

Results of this study indicate that the poor prognosis that has been ascribed to the pre-B immunophenotype in childhood ALL appears to be restricted to children with translocations, particularly the t(1;19) (q23;p13). Randomized trials often rely on some form of stratification to ensure comparability among patient groups; these preliminary results suggest that knowledge of chromosomal translocations is important for study design. Children who have pre-B ALL without a translocation have a treatment outcome at least as good as that of children who have early pre-B ALL without a translocation in the context of this therapy. Our findings that chromosomal translocations are associated with a poor treatment outcome in early pre-B and pre-B ALL confirm previous observations.⁸⁻¹⁰

The finding showing that children with pre-B ALL and a t(1;19) have an even worse estimated EFS than those with other translocations is not surprising. Other specific chromosomal translocations, such as t(9;22) (q34;q11), have previously been shown to confer an especially poor prognosis.²¹⁻²³ Approximately 25% of children with ALL have a pre-B immunophenotype,²⁴ and a similar proportion of children with pre-B ALL have a t(1;19). Because of the frequency of the t(1;19) and its strong association with a poor prognosis, this chromosomal translocation assumes special importance for therapy planning.

Two consecutive trials of the POG¹¾ showed that children with pre-B ALL had poorer survival than those with early pre-B ALL. The greater proportions of black patients and of patients with higher leukocyte counts within the pre-B patient subgroup partially explain the less favorable treatment response. Here we show that both black race and higher leukocyte counts are strongly associated with t(1;19) within the pre-B phenotype. However, both of our previous studies (ALINc 12 and 13) indicated independent prognostic importance for the pre-B immunophenotype.²⁴ We have not yet demonstrated a worse overall EFS for children with pre-B ALL as compared to those with early pre-B ALL in this ALINc 14 study, in contrast to our previous findings. The
reason for this discrepancy is unclear, but it may be due to significant improvement in early EFS in this study compared with our other trials or, less likely, to the short follow-up of patients treated in this study.

Previous studies have been unable to define specific subgroups of pre-B cases with a worse prognosis. Recently, Pui et al.9 showed that, within the pre-B phenotype, patients with chromosomal translocations had a significantly higher incidence of traditional high-risk factors, including black race, higher WBC level, DNA index ≤ 1.16, and higher lactate dehydrogenase levels.5,9 Our data extend our previous findings and those of Pui et al by showing the independent prognostic importance of the t(1;19) in children with pre-B ALL.

Mellentien et al.24 recently found that the E2A gene, which encodes proteins with properties of the Ig enhancer-binding factors E12 and E47, maps to chromosome region 19p13.2-p13.3, the breakpoint region noted on chromosome 19 in the t(1;19). All 10 pre-B leukemias or cell lines carrying the t(1;19) contained rearrangements of the E2A gene. These rearrangements altered the E2A transcriptional unit, resulting in the synthesis of a transcript larger than the normalized E2A messenger RNAs (mRNAs) in one cell line studied. Subsequently, Nourse et al.25 and Kamps et al.26 identified cDNAs encoding an 85-kD fusion protein that has the features of a chimeric transcription factor in which the DNA binding domain of E2A is replaced by the putative DNA binding domain of a homeoprotein from chromosome 1 which they named Prl. They demonstrated further that an identical E2A-Prl mRNA junction was created in several t(1;19) cell lines, indicating that the fusion transcripts and predicted chimeric protein are consistently observed in this translocation. Based on this information it may be concluded that this fusion protein is likely to contribute to the ALL phenotype by directly altering the expression of genes normally responsive to the Prl homeoprotein.

ACKNOWLEDGMENT

We thank Christy Wright for editorial assistance and Peggy Vendiveer for typing the manuscript.

REFERENCES


Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study

WM Crist, AJ Carroll, JJ Shuster, FG Behm, M Whitehead, TJ Vietti, AT Look, D Mahoney, A Ragab and DJ Pullen

Updated information and services can be found at:
http://www.bloodjournal.org/content/76/1/117.full.html

Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml